Literature DB >> 3435101

Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.

D Havlichek1, L Saravolatz, D Pohlod.   

Abstract

We evaluated the in vitro susceptibility of Legionella pneumophila ATCC 33152 (serogroup I) to 13 antibiotics alone and in combination with rifampin (0.1 mg/liter) by three methods. Extracellular susceptibility was determined by MIC determinations and time kill curves in buffered yeast extract broth, while intracellular susceptibility was determined by peripheral human monocytes in RPMI 1640 culture medium. Antibiotic concentrations equal to or greater than the broth dilution MIC inhibited or killed L. pneumophila by the time kill method, except this was not the case for trimethoprim-sulfamethoxazole. Antibiotic concentrations below the broth dilution MIC did not inhibit Legionella growth. The only antibiotic-rifampin combinations which produced improved killing of L. pneumophila by the time kill method were those in which the logarithmic growth of L. pneumophila occurred during the experiment (rosoxacin, amifloxacin, cinoxacin, trimethoprim-sulfamethoxazole, clindamycin, and doxycycline). Neither direct MICs nor time kill curve assays accurately predicted intracellular L. pneumophila susceptibility. Rifampin, erythromycin, ciprofloxacin, rosoxacin, enoxacin, amifloxacin, gentamicin, clindamycin, and doxycycline all inhibited intracellular L. pneumophila growth at readily achievable concentrations in serum. Cefoxitin and thienamycin showed no inhibition of growth, although they were present extracellularly at concentrations that were 20 to 1,000 times their broth dilution MICs. Clindamycin was the only antibiotic that was able to inhibit intracellular L. pneumophila growth at an extracellular concentration below its MIC. The gentamicin (5 mg/liter)-rifampin combination was the only antibiotic-rifampin combination which demonstrated decreased cell-associated Legionella survival in this model of in vitro susceptibility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435101      PMCID: PMC174984          DOI: 10.1128/AAC.31.10.1529

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

2.  Antibiotic uptake by alveolar macrophages.

Authors:  J D Johnson; W L Hand; J B Francis; N King-Thompson; R W Corwin
Journal:  J Lab Clin Med       Date:  1980-03

3.  Antimicrobial susceptibility of intracellular Legionella pneumophila.

Authors:  M A Bacheson; H M Friedman; C E Benson
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  Legionnaires' disease: description of an epidemic of pneumonia.

Authors:  D W Fraser; T R Tsai; W Orenstein; W E Parkin; H J Beecham; R G Sharrar; J Harris; G F Mallison; S M Martin; J E McDade; C C Shepard; P S Brachman
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

6.  Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

7.  Chronic granulomatous disease: mode of action of sulfamethoxazole/trimethoprim.

Authors:  F K Gmünder; R A Seger
Journal:  Pediatr Res       Date:  1981-12       Impact factor: 3.756

8.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 9.  Legionella infections: a review of five years of research.

Authors:  R D Meyer
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Antibiotic treatment of guinea-pigs infected with agent of Legionnaires' disease.

Authors:  D W Fraser; I Wachsmuth; C Bopp; J C Feeley; T F Tsai
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

View more
  22 in total

Review 1.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 4.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Subinhibitory concentrations of antimicrobial agents reduce the uptake of Legionella pneumophila into Acanthamoeba castellanii and U937 cells by altering the expression of virulence-associated antigens.

Authors:  P C Lück; J W Schmitt; A Hengerer; J H Helbig
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; M A Franke; P B Michelsen
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Ren; R Polzer; R P Gladue
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.

Authors:  P Rajagopalan-Levasseur; E Dournon; G Dameron; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.